To the Editor Chen et al1 are commended for reporting the final results of a phase 1/2, single-arm trial of chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose as treatment for unresectable locally advanced esophageal cancer. The authors presented exploratory comparisons with an institutional cohort of 97 patients who received standard-dose radiotherapy and found that patients who received a simultaneous integrated boost of radiation had superior local control and overall survival. Although we appreciate the intention of using historical controls to augment evidence generated from single-arm trials, we note that such analyses and reporting require careful planning and rigorous disseminations.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Fan L, Li B, Hu C. Using Real-world Historical Controls to Evaluate Radiation Dose Escalation in Esophageal Cancer. JAMA Oncol. Published online February 06, 2020. doi:10.1001/jamaoncol.2019.6406
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: